INT46672

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 1982
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 1.84
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (HBE1) transport (HBE1)
Anatomy Link Frequency
A549 1
NL20 1
H460 1
HBE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 1 84.16 Quite High
Inflammation 10 29.88 Quite Low
Potency 8 5.00 Very Low Very Low Very Low
peripheral neuropathy 4 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
Glutamate 3 5.00 Very Low Very Low Very Low
Spinal cord 2 5.00 Very Low Very Low Very Low
neuralgia 2 5.00 Very Low Very Low Very Low
Sciatic nerve 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatitis B Virus Infection 114 98.82 Very High Very High Very High
Hepatitis 68 94.48 High High
Arthralgia 1 84.64 Quite High
Immunization 1 82.88 Quite High
Chronic Hepatitis 18 50.00 Quite Low
Cirrhosis 4 29.88 Quite Low
Hepatocellular Cancer 4 26.12 Quite Low
Infection 4 22.64 Low Low
Cancer 312 5.00 Very Low Very Low Very Low
Lung Cancer 162 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the GLOBE trial, the primary outcome was a “therapeutic response” which was defined as a decrease in the HBV DNA level to <5 log copies/mL along with either a loss of HBeAg or ALT normalization.
Localization (normalization) of HBeAg associated with hepatitis b virus infection
1) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.53 Pain Relevance 0
Secondary endpoints included the proportion of subjects with HBV DNA < 5 log copies/mL and proportion undetectable at one year, normalization of ALT, HBeAg loss, HBeAg seroconversion and therapeutic response, as defined in the GLOBE trial.
Localization (normalization) of HBeAg associated with hepatitis b virus infection
2) Confidence 0.02 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.58 Pain Relevance 0
HBE4, NL20, A549, H460, H1435, H292, H23, H358, H1299, H1993, H1395, and H838 cells were purchased from American Type Culture Collection (Manassas, Virginia, United States) and cultured under recommended conditions.
Localization (cultured) of HBE4 in H460
3) Confidence 0.01 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1584412 Disease Relevance 0 Pain Relevance 0
HBE4, NL20, A549, H460, H1435, H292, H23, H358, H1299, H1993, H1395, and H838 cells were purchased from American Type Culture Collection (Manassas, Virginia, United States) and cultured under recommended conditions.
Localization (cultured) of HBE4 in A549
4) Confidence 0.00 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1584412 Disease Relevance 0 Pain Relevance 0
HBE4, NL20, A549, H460, H1435, H292, H23, H358, H1299, H1993, H1395, and H838 cells were purchased from American Type Culture Collection (Manassas, Virginia, United States) and cultured under recommended conditions.
Localization (cultured) of HBE4 in NL20
5) Confidence 0.00 Published 2006 Journal PLoS Medicine Section Body Doc Link PMC1584412 Disease Relevance 0 Pain Relevance 0
Decreased ALT and HBeAg clearance, however, did not seem to be related to vaccination, and the transient ALT elevations appeared to represent sporadic, acute non-A, non-B hepatitis.
Localization (clearance) of HBeAg associated with hepatitis
6) Confidence 0.00 Published 1982 Journal Ann. Intern. Med. Section Abstract Doc Link 7073149 Disease Relevance 0.73 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox